Sign inJoin waitlistJoin the waitlist

Jennifer Specht

Clinical Research Director, Breast Oncology, UW Medicine · University of Washington School of Medicine

Credentials: · · ·

History

Breast Oncology · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

University of Washington
2002–2004
Internal Medicine
University of Washington School of Medicine
1999–2002
University of Washington School of Medicine
1995–1999
University of Washington
1991–1995

Research

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
Cancer Cell · 2021 · 274 citations
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
The Journal of Experimental Medicine · 1997 · First of 8 authors · 250 citations
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer
Journal of Clinical Oncology · 2014 · 239 citations

Hannah Linden
29 papers
David Mankoff
23 papers
JG
Julie Gralow
15 papers
Vk Gadi
12 papers
Janie Lee
10 papers · 5 as a resident
Lisa Carey
10 papers
Eric Winer
9 papers
IK
Ian Krop
9 papers
Mothaffar Rimawi
9 papers
Vandana Abramson
9 papers
AW
Antonio Wolff
8 papers
RL
Robert Livingston
8 papers

Grants

Role of ctDNA Change as a Response Measure in the EA1183 Patient Population and How ctDNA Changes Correlate with Metabolic Response by Serial FDG PET/CT
National Cancer Institute · R01
Contact PI · $1.5M · University of Washington
2021–2027
PET to Measure Breast Cancer Bone Metastasis Response
National Cancer Institute · R01
Contact PI · $362.5K · University of Washington
2007–2014

Clinical trials

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
University of Washington
2026–2030
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Principal investigator · Active not recruiting · Phase 2
ECOG-ACRIN Cancer Research Group
2020–2027
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Principal investigator · Withdrawn · Phase 2
University of Washington
2019–2022
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
Principal investigator · Terminated
University of Washington
2011–2022